InflaRx N.V., a clinical-stage biopharmaceutical company specializing in C5a technology, is making waves in Germany and the United States with its unique inhibitors. C5a, an inflammatory mediator involved in the progression of a variety of autoimmune and inflammatory diseases, is the focus of the company's research. In particular, InflaRx N.V.'s lead product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that has completed Phase III clinical trials for the treatment of hidradenitis suppurativa, pyoderma gangraenosum, anti-neutrophil cytoplasm antibody associated vasculitis, and PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma. In addition to vilobelimab, the company is developing oral small molecule drug candidate INF904 and IFX002, a pre-clinical development-stage treatment for chronic inflammation and autoimmune diseases. InflaRx N.V. has also entered co-development and clinical trial collaboration and supply agreements with Beijing Defengrei Biotechnology Co. Ltd. and Merck & Co. Inc., respectively. The company, formerly known as Fireman B.V., was founded in 2007 and is based in Jena, Germany.
InflaRx N.V.'s ticker is IFRX
The company's shares trade on the NASDAQ stock exchange
They are based in Jena, Germany
There are 11-50 employees working at InflaRx N.V.
It is http://www.inflarx.de/
InflaRx N.V. is in the Healthcare sector
InflaRx N.V. is in the Biotechnology industry
The following five companies are InflaRx N.V.'s industry peers: